Loading...
Loading...
MDNA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,437.0K |
| Operating I/L | -6,809.0K |
| Other Income/Expense | 1,372.0K |
| Interest Income | 342.0K |
| Pretax | -3,723.0K |
| Income Tax Expense | -1,714.0K |
| Net Income/Loss | -3,723.0K |
Medicenna Therapeutics Corp. is an immunotherapy company specializing in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product, MDNA55, has completed Phase IIb clinical trial for recurrent glioblastoma and is in development for other brain and non-brain tumors. The company also offers MDNA11, MDNA209, MDNA413, and MDNA132, targeting various diseases including cancer, autoimmune diseases, and solid tumors. Additionally, Medicenna provides the BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines.
